The DCHA Board of Directors launched the Board Quality Initiative in 2013 to work collaboratively to raise quality across all member hospitals. In addition, they envisioned providing a mechanism for designing innovative approaches to solving challenging issues faced by our hospitals.
The Carbapenem-resistant Enterobacteriaceae (CRE) Point Prevalence Study was designed through multiple DCHA Committees, working in collaboration with the four sponsoring partners, DCHA, Department of Health (DOH), DC Public Health Lab (PHL), and OpGen, a molecular testing and bioinformatics company. Funding was secured through a CDC grant to DOH, DCHA and PHL.
Representatives from the CRE Point Prevalence Study Team, comprised of DCHA, DOH, PHL and OpGen, met at DCHA yesterday to discuss the outcomes of facility meetings to date, and the logistics for upcoming trainings and sample collections. Two training sessions occurred this week, with teams at MedStar Washington Hospital Center and Transitions Healthcare. Next week, samples will be collected at both facilities.
Training sessions and sample collection dates have been scheduled for most participating facilities, though a few are still working to confirm dates.
Samples collected will be screened by PHL for quality and tested by OpGen for CRE prevalence, phenotypes and genotypes. Each facility will be able to view their results within 24-48 hours from sample collection through the OpGen web portal. Login information will be provided to designated facility team members. The study team will provide aggregate data for all facilities once complete.
The study team has received positive feedback from participants, and we look forward to a very successful implementation of the study.